Literature DB >> 29531396

Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review.

Duane Bates1, Jenny Edwards1, Jeffrey Shrum2, Casey Chan3, Sharita Manga4, Elizabeth MacKay5.   

Abstract

Entities:  

Year:  2018        PMID： 29531396      PMCID： PMC5842050     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  24 in total

Review 1.  Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis.

Authors:  K Boonyawat; F Caron; A Li; C Chai-Adisaksopha; W Lim; A Iorio; R D Lopes; D Garcia; M A Crowther
Journal:  J Thromb Haemost       Date:  2017-05-09       Impact factor: 5.824

2.  Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.

Authors:  Suzanne J Francart; Emily M Hawes; Allison M Deal; Dorothy M Adcock; Robert Gosselin; Cheryl Jeanneret; Kenneth D Friedman; Stephan Moll
Journal:  Thromb Haemost       Date:  2014-01-09       Impact factor: 5.249

Review 3.  Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.

Authors:  Susan E Conway; Andrew Y Hwang; Charles D Ponte; John G Gums
Journal:  Pharmacotherapy       Date:  2017-02-03       Impact factor: 4.705

Review 4.  Thrombosis in the setting of obesity or inflammatory bowel disease.

Authors:  Steven R Lentz
Journal:  Blood       Date:  2016-11-17       Impact factor: 22.113

5.  Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.

Authors:  Karlyn Martin; Stephan Moll
Journal:  Thromb Res       Date:  2016-04-26       Impact factor: 3.944

6.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

7.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Authors:  Wolfgang Mueck; Anthonie W A Lensing; Giancarlo Agnelli; Hervé Decousus; Paolo Prandoni; Frank Misselwitz
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

8.  Complication rates after hip or knee arthroplasty in morbidly obese patients.

Authors:  Richard J Friedman; Susanne Hess; Scott D Berkowitz; Martin Homering
Journal:  Clin Orthop Relat Res       Date:  2013-05-14       Impact factor: 4.176

Review 9.  Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.

Authors:  Wolfgang Mueck; Jan Stampfuss; Dagmar Kubitza; Michael Becka
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

10.  Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.

Authors:  Kozue Ikeda; Hideaki Tachibana
Journal:  J Arrhythm       Date:  2015-09-15
View more
  1 in total

1.  Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.

Authors:  Majdoleen Alalawneh; Ahmed Awaisu; Ousama Rachid
Journal:  Clin Pharmacokinet       Date:  2022-10-06       Impact factor: 5.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.